Skip to main content
Fig. 3 | Insights into Imaging

Fig. 3

From: Cancer genome landscape: a radiologist’s guide to cancer genome medicine with imaging correlates

Fig. 3

RTK-RAS pathway. a Image showing the RAS-RTK pathway, activated by epithelial growth factor (EGF) and its receptor (EGFR). RAS and EGF/EGFR activate PI3K-RAS-mTORC and RAS-RAF-MEK pathways, determining cell proliferation and cell growth. The pathway is blocked by EGF antibodies, such as cetuximab or EGFR inhibitors such as erlotinib or afatinib (bd) contrast-enhanced CT images of the chest 64-year-old woman with multifocal adenocarcinoma of the lung with mutation of the EGFR exon 21. Patient was initially treated with erlotinib and follow up CT (b) at 2 months after treatment was started shows mild improvement of the lung consolidative opacities compared to baseline CT of the chest (a). Patient developed erlotinib associated shortness of breath and rash, and was switched to another EGFR inhibitor, afatinib. c CT of the chest performed 6 months after afatinib was started, shows significant resolution of the consolidations and of the interlobular thickening

Back to article page